D
David W. Hein
Researcher at University of Louisville
Publications - 271
Citations - 13099
David W. Hein is an academic researcher from University of Louisville. The author has contributed to research in topics: Genotype & Arylamine N-acetyltransferase. The author has an hindex of 56, co-authored 246 publications receiving 12467 citations. Previous affiliations of David W. Hein include University of Michigan & University of South Carolina.
Papers
More filters
Journal Article
Metabolic gene polymorphism frequencies in control populations.
Seymour Garte,Laura Gaspari,A.-K. Alexandrie,Christine B. Ambrosone,Herman Autrup,Judith L. Autrup,H. Baranova,L. Bathum,Simone Benhamou,Paolo Boffetta,C. Bouchardy,K. Breskvar,J. Brockmöller,Ingolf Cascorbi,Margie L. Clapper,Christiane Coutelle,Ann K. Daly,Marco Dell'Omo,Vita Dolzan,C.M. Dresler,Anthony A. Fryer,Aage Haugen,David W. Hein,Allan Hildesheim,Ari Hirvonen,L.L. Hsieh,Magnus Ingelman-Sundberg,Ivan Kalina,Daehee Kang,Masahiro Kihara,Chikako Kiyohara,Pierre Kremers,Philip Lazarus,Loic Le Marchand,Maria Celeste Lechner,E.M.M. van Lieshout,Stephanie J. London,Johannes J. Manni,Christine Maugard,S. Morita,Valle Nazar-Stewart,K. Noda,Yoshio Oda,Fritz F. Parl,Roberta Pastorelli,I. Persson,Wilbert H.M. Peters,Agneta Rannug,Timothy R. Rebbeck,Angela Risch,L. Roelandt,Marjorie Romkes,David Ryberg,Salagovic J,Bernadette Schoket,Janeric Seidegård,Peter G. Shields,Edith Sim,D. Sinnet,Richard C. Strange,Isabelle Stücker,Haruhiko Sugimura,Jordi To-Figueras,Paolo Vineis,M.C. Yu,Emanuela Taioli +65 more
TL;DR: Using the International Project on Genetic Susceptibility to Environmental Carcinogens (GSEC) database containing information on over 15,000 control (noncancer) subjects, the allele and genotype frequencies for many of the more commonly studied metabolic genes in the human population were determined.
Journal Article
Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms.
David W. Hein,Mark A. Doll,Adrian J. Fretland,Matthew A. Leff,Stephanie J. Webb,Gong H. Xiao,Udaya Sankar Devanaboyina,Norma A. Nangju,Yi Feng +8 more
TL;DR: Large-scale molecular epidemiological studies that investigate the role of NAT1 and NAT2 genotypes and/or phenotypes together with other genetic susceptibility gene polymorphisms and biomarkers of carcinogen exposure are necessary to expand the current understanding of the roles of NAT2 acetylation polymorphisms in cancer risk.
Journal ArticleDOI
NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.
Montserrat Garcia-Closas,Núria Malats,Debra T. Silverman,Mustafa Dosemeci,Manolis Kogevinas,David W. Hein,Adonina Tardón,Consol Serra,Alfredo Carrato,Reina García-Closas,Josep Lloreta,Gemma Castaño-Vinyals,Meredith Yeager,Robert Welch,Stephen J. Chanock,Nilanjan Chatterjee,Sholom Wacholder,Claudine Samanic,Montserrat Torà,Francisco J. Martín Fernández,Francisco X. Real,Nathaniel Rothman +21 more
TL;DR: The GSTM1 null genotypes increases the overall risk of bladder cancer, and the NAT2 slow-acetylator genotype increases risk particularly among cigarette smokers, providing compelling evidence for the role of common polymorphisms in the aetiology of cancer.
Journal ArticleDOI
Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis.
TL;DR: The high frequency of the NAT1 and NAT2 acetylation polymorphisms in human populations together with ubiquitous exposure to aromatic and heterocyclic amines suggest that NAT 1 and NAT 2 acetylator genotypes are important modifiers of human cancer susceptibility.